ID   KP-MRT-RY
AC   CVCL_7051
SY   KPMRTRY; Kyoto Pediatrics-Malignant Rhabdoid Tumor-RY
DR   BioSample; SAMN10989607
DR   cancercelllines; CVCL_7051
DR   Cell_Model_Passport; SIDM01655
DR   DepMap; ACH-001109
DR   Wikidata; Q54900383
RX   CelloPub=CLPUB00599;
RX   PubMed=18281554;
RX   PubMed=21871868;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C8715; Rhabdoid tumor of the kidney
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 16
//
RX   CelloPub=CLPUB00599;
RA   Sugimoto T., Kuroda H., Kuwahara Y., Katsumi Y., Misawa A.,
RA   Moritake H., Hosoi H.;
RT   "Cellular and molecular characteristics of established childhood
RT   soft-tissue sarcoma cell lines.";
RL   J. Cancer Res. Therap. Oncol. 7:202.1-202.12(2019).
//
RX   PubMed=18281554; DOI=10.1158/1078-0432.CCR-07-1661;
RA   Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K.,
RA   Iehara T., Kuroda H., Hosoi H., Sugimoto T.;
RT   "Trastuzumab activates allogeneic or autologous antibody-dependent
RT   cellular cytotoxicity against malignant rhabdoid tumor cells and
RT   interleukin-2 augments the cytotoxicity.";
RL   Clin. Cancer Res. 14:1192-1199(2008).
//
RX   PubMed=21871868; DOI=10.1016/j.bbrc.2011.08.047;
RA   Katsumi Y., Iehara T., Miyachi M., Yagyu S., Tsubai-Shimizu S.,
RA   Kikuchi K., Tamura S., Kuwahara Y., Tsuchiya K., Kuroda H.,
RA   Sugimoto T., Houghton P.J., Hosoi H.;
RT   "Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is
RT   inversely correlated with p16 expression.";
RL   Biochem. Biophys. Res. Commun. 413:62-68(2011).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//